# Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

> **NCT05837689** · — · UNKNOWN · sponsor: **Xiaojun Xu** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, Pediatric

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT05837689
- **Lead sponsor:** Xiaojun Xu
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04
- **Primary completion:** 2023-04
- **Final completion:** 2023-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05837689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05837689, "Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05837689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*